Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection

Go back to Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
(NASDAQ: ACXP) Delayed: 1.15 +0.01 (0.88%)
Previous Close $1.14    52 Week High $ 
Open $1.18    52 Week Low $ 
Day High $1.18    P/E N/A 
Day Low $1.13    EPS $ 
Volume 20,962